Skip to content

Study on the effects of xylooligosaccharides(XOS) on Gastrointestinal and Immune function in liver cancer patients undergoing interventional therapy

Study on the effects of xylooligosaccharides(XOS) on Gastrointestinal and Immune function in liver cancer patients undergoing interventional therapy

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR2500097152
Enrollment
Unknown
Registered
2025-02-13
Start date
2025-03-01
Completion date
Unknown
Last updated
2025-02-17

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Hepatocellular carcinoma

Interventions

Constipated group:Xylooligosaccharides (XOS-95 type) powder (3 g per sachet) for oral administration
Diarrheal group:Xylooligosaccharides (XOS-95 type) powder (1.5 g per sachet) for oral administration

Sponsors

Affiliation Hospital of JiangNan University
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 80 Years

Inclusion criteria

Inclusion criteria: Inclusion criteria for patients with constipation (1) Liver cancer patients whose clinical or pathological diagnosis met the criteria for Diagnosis and Treatment of primary liver Cancer (2024 edition); (2) Age >=18 years old; (3) Child-Pugh score =18 years old; (3) Child-Pugh score <=7, Eastern Cooperative Oncology Group (ECOG) performance status 0 or 1; (4) BMI 18.5-28; (5) The patient had diarrhea during the perioperative period, which met the diagnostic criteria for diarrhea and had stool type 6-7 based on the Bristol stool Form Scale; (6) Did not receive the initial treatment and did not participate in other clinical research at least one week before entering the study; (7) Voluntarily participated in this study and signed the informed consent.

Exclusion criteria

Exclusion criteria: 1: The presence of other malignant tumors; 2: Expected survival time of less than 6 months; 3: Presence of severe complications such as serious cardiopulmonary dysfunction, coagulopathy, or decompensated liver cirrhosis; 4: Use of antibiotics and probiotic products (including long-term consumption of yogurt and probiotic drinks) within the past three months; 5: Poor compliance, unable to adhere to the clinical trial protocol for oral xylooligosaccharides.

Design outcomes

Primary

MeasureTime frame
Patient gastrointestinal function status score.;Fecal microbiota.;Blood sample (blood routine examination, liver function, tumor markers, and immune cell status);

Secondary

MeasureTime frame
Progression Free Survival;Overall survivial;

Countries

China

Contacts

Public ContactWu Qinghua

Affiliation Hospital of JiangNan University

wqhsusan@126.com+86 139 6182 7470

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026